The purpose of this study is to determine target dose range of buprenorphine/naloxone
combination tablet that provides therapeutic response in opiate addicts with low to moderate
dependence, and to identify appropriate initial induction dose in opiate addicts with low to
Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported
use within the last 30 days, agreeable to conditions of study and signed informed consent
Psychiatric disorder that requires medication therapy, history of seizures, pregnant
and/or nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics,
acute hepatitis, other medical conditions that deem participation to be unsafe.